LONDON--(Marketwire - Nov 13, 2012) - The drug related products industry, which features companies such as Perrigo Co. and Auxilium Pharmaceuticals Inc., has been making headlines of late. Several companies have turned in solid quarterly reports, and a plethora of acquisitions and new product launches has kept the industry in the limelight. With president Obama remaining in the White House, companies in the industry could also stand to benefit from his Affordable Health Care Act, as more Americans will be insured.
www.WallStreetActive.com is unswerving when it comes teaching the new and pro traders on how to take the helm in a market environment that has been seeing waves upon waves of changes and reap the rewards of participating in various sectors. We invite serious traders to join our financial community so that they can benefit from our free analytical coverage on Perrigo Co. (
With earnings season in full swing, investors have been able to take a closer look at individual companies in the industry. Some, like Perrigo, have reported increased sales from their over-the-counter products, while others have seen their prescription segments grow. Analyst opinion on Perrigo Co. accessible for free at
The industry is facing a number of headwinds though. Research and development costs remain high, and offer no guarantee on investment. Yet some, like Auxilium Pharmaceuticals, recently posted a decline of 25.4% in its R&D expenses as a result of inferior spending on its Peyronie's studies. See what our analysts have to say on Auxilium Pharmaceuticals Inc. Follow the Link below
Competition in the industry is fierce, and in some cases has led to legal battles. That being said, the industry has been turning in solid numbers, and could continue to do so for the remainder of the year.
About Wall Street Active:
Walls Street Active offers topmost independent research and investment strategies with the sole purpose of consistently identifying stocks that provide the biggest return on investment for our subscribers. We provide sharp North American stock investing opinion with a truly outstanding success rate. Our goal is for likeminded traders to make a lot of money through our information.
Read our Disclaimer